Liu Chunshui, Wang Cong, Du Zhonghua, Xue Hongwei, Liu Zhihe
Department of Hematology, The First Hospital of Jilin University, Changchun.
Department of Lymphoma, The Affiliated Hospital of Qingdao University, Qingdao, China.
Medicine (Baltimore). 2020 Oct 30;99(44):e22904. doi: 10.1097/MD.0000000000022904.
This study was to investigate clinical features and prognosis of duplex primary malignant neoplasms involving chronic myeloid leukemia (CML-DPMNs). Clinical data of thirteen CML-DPMN patients who were admitted to the First Hospital of Jilin University from May 2008 to December 2018 were collected and retrospectively analyzed. Female patients (9/13) were predominant in this cohort study. Nine patients were metachronous DPMNs (metachronous duplex primary malignant neoplasms involving chronic myeloid leukemia) with 5 years median interval time from primary malignancy to secondary malignancy. The other 4 patients were diagnosed as synchronous CML-DPMNs. Seven of the metachronous duplex primary malignant neoplasms involving chronic myeloid leukemia suffered from CML following many years of comprehensive anti-cancer therapy. Two of CML-MDPMN patients had invasive ductal carcinoma of breast after many years of treatment with imatinib. There was no difference between treatment-related CML group and non-treatment-related CML group in regard as the gender, age, white blood cell count, hemoglobin level, platelet count, and risk level. The median overall survival time of these thirteen patients with CML-DPMNs was not reached. In conclusion, female patients are more likely to suffer from the CML-DPMNs in the present article. Overall survival time of patients with DPMNs involving CML could be promising if timely and effective treatment therapy is adopted.
本研究旨在探讨合并慢性髓性白血病的双原发恶性肿瘤（CML-DPMNs）的临床特征及预后。收集了2008年5月至2018年12月期间入住吉林大学第一医院的13例CML-DPMN患者的临床资料，并进行回顾性分析。在这项队列研究中，女性患者占主导（9/13）。9例为异时性DPMNs（合并慢性髓性白血病的异时性双原发恶性肿瘤），从原发性恶性肿瘤到继发性恶性肿瘤的中位间隔时间为5年。另外4例被诊断为同步性CML-DPMNs。7例合并慢性髓性白血病的异时性双原发恶性肿瘤患者在经过多年综合抗癌治疗后患上慢性髓性白血病。2例CML-MDPMN患者在接受伊马替尼治疗多年后发生乳腺浸润性导管癌。在性别、年龄、白细胞计数、血红蛋白水平、血小板计数和风险水平方面，治疗相关的CML组和非治疗相关的CML组之间没有差异。这13例CML-DPMN患者的中位总生存时间未达到。总之，在本文中女性患者更易患CML-DPMNs。如果采取及时有效的治疗，合并慢性髓性白血病的双原发恶性肿瘤患者的总生存时间可能较好。
